Effects of electroacupuncture combined with paliperidone palmitate long-acting injection on withdrawal symptoms and neurotransmitters in methamphetamine addicts

被引:0
|
作者
Chen, Yu [1 ]
Wei, Wen-Jie [1 ]
Gong, Ji-Fen [1 ]
Qiao, Juan [1 ]
Wu, Chun-Xi [1 ]
Wang, Xiao-Jun [1 ]
Ding, Ying [1 ]
Chen, Hong-Yuan [1 ]
Lu, Hua-Xin [1 ]
Li, Ming-Chao [2 ]
Ji, Qiu-Ming [1 ]
机构
[1] Wuhan Wudong Hosp, Dept Psychiat, 46 Wudong St, Wuhan 430084, Peoples R China
[2] Wuhan Mental Hlth Ctr, Dept Psychiat, Wuhan, Peoples R China
关键词
Electroacupuncture treatment; methamphetamine; neurotransmitters; paliperidone palmitate long-acting injection; CLINICAL-PHARMACOLOGY; SCHIZOPHRENIA; NEUROTOXICITY;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
. Objective. To investigate the effects of electroacupuncture combined with paliperidone palmitate long-acting injection (PP-LAI) on withdrawal symptoms and neurotransmitters in methamphetamine (MA) addicts. Materials and methods. A total of 109 methamphetamine addicts, who were treated in the hospital from October 2021 to October 2022, were selected. According to the random number table, the patients were divided into the study group (n=54) and the control group (n=55), in which the control group was treated with PP-LAI and the study group was treated with electroacupuncture on the basis of the control group; the methamphetamine withdrawal symptom score scale was used to assess the therapeutic effect before treatment and within 12 months after treatment; the changes of brain neurotransmitters dopamine, gamma-aminobutyric acid, serotonin, acetylcholine values were compared between the two groups. Results .1) There was no statistical difference in MA withdrawal symptom scores between the two groups before treatment (p>0.05); 2) MA withdrawal symptom scores have a statistically significant difference between the study group and the control group after 3 and 6 months of treatment; 3) dopamine levels in the study group were significantly higher than those in the control group after 6 months of completion of treatment, and gamma-aminobutyric acid values and 5- serotonin values in the study group were significantly lower than those in the control group (p<0.05). Conclusions. Electroacupuncture combined with PP-LAI can partially improve the withdrawal symptoms and anxiety of methamphetamine addicts. This is a potential treatment for preventing relapse of withdrawal symptoms.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 50 条
  • [41] Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report
    Wang, Feng
    Chen, Juan
    Guo, Linglin
    Li, Zhixiong
    Li, Zhe
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [42] Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
    Corbeil, Olivier
    Essiambre, Anne-Marie
    Bechard, Laurent
    Roy, Audrey-Anne
    Huot-Lavoie, Maxime
    Brodeur, Sebastien
    Chandrasena, Ranjith
    Theriault, Chantale
    Crocker, Candice
    Melun, Jean-Pierre
    Tibbo, Phil
    Demers, Marie-France
    Roy, Marc-Andre
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2022, 12
  • [43] Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    EARLY INTERVENTION IN PSYCHIATRY, 2020, 14 (04) : 428 - 438
  • [44] Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle Are They Therapeutically Equivalent?
    Ravenstijn, Paulien
    Samtani, Mahesh
    Russu, Alberto
    Hough, David
    Gopal, Srihari
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (06) : 744 - 745
  • [45] Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle Are They Therapeutically Equivalent?
    Yin, John
    Collier, Abby C.
    Barr, Alasdair M.
    Honer, William G.
    Procyshyn, Ric M.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (04) : 447 - 449
  • [46] Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
    Di Lorenzo, Rosaria
    Iorio, Anita
    Pinelli, Margherita
    Magarini, Federica
    Marchi, Mattia
    Sacchetti, Andrea
    Calogero, Chiara
    Galeazzi, Gian Maria
    Ferri, Paola
    Rovesti, Sergio
    Minarini, Alessandro
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 829 - 846
  • [47] The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial
    Koshikawa, Yosuke
    Takekita, Yoshiteru
    Kato, Masaki
    Sakai, Shiho
    Onohara, Ai
    Sunada, Naotaka
    Nishida, Keiichiro
    Yoshimura, Masafumi
    Fabbri, Chiara
    Serretti, Alessandro
    Kinoshita, Toshihiko
    NEUROPSYCHOBIOLOGY, 2016, 73 (01) : 35 - 42
  • [48] Impact of long-acting buprenorphine injection on methamphetamine use: A retrospective cohort study
    Raza, M.
    Abeysundera, H.
    Branjerdporn, G.
    AUSTRALASIAN PSYCHIATRY, 2023, 31 (05) : 690 - 693
  • [49] Protocol proposal for switching long-acting antipsychotic medication in psychotic patients: from fluphenazine decanoate to paliperidone palmitate
    Boix, E.
    Niubo, M.
    Davi, E.
    Esteban, R.
    Moreno, L.
    Vilella, V.
    Alonso, I.
    Borras, M.
    Diez, O.
    Horta, A.
    Sobotkiewiczova, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S566 - S566
  • [50] Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension
    Procyshyn, Ric M.
    Lamoure, Joel W.
    Katzman, Martin A.
    Skinner, Pamela L.
    Sherman, Stephen E.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2019, 22 : 548 - 566